Abstract
One hundred thirty-three patients with advanced pancreatic adenocarcinoma and measurable disease were treated with 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM), streptozotocin plus mitomycin C plus 5-FU (SMF) in the regimen originally reported, and streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses. Respective response rates for all patients were 13%, 15%, and 14%, and for previously untreated patients, 14%, 14%, and 15%. Median survivals for all previously untreated patients range from 3 months (FAM) to 4 1/2 months (original SMF). Predominant toxic reactions were vomiting, leukopenia, and thrombocytopenia. Without evidence of greater therapeutic benefit, none of these regimens should be used in the routine treatment of advanced pancreatic carcinoma.
Publisher
American Society of Clinical Oncology (ASCO)
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pancreatic Cancer;Clinical Radiation Oncology;2017-05-05
2. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer;Advanced Drug Delivery Reviews;2010-03
3. Systemic therapy for metastatic pancreatic adenocarcinoma;Therapeutic Advances in Medical Oncology;2010-02-12
4. Tumors of the Pancreas;Sleisenger and Fordtran's Gastrointestinal and Liver Disease;2010
5. Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer;Pancreatic Cancer;2008